Abstract
Progestins were the first drugs to be used in systemic therapy of endometrial cancer. After four decades of clinical trials, their role has been narrowed to a relatively small percentage of tumors that have metastasized but are well differentiated and rich in hormonal receptors. Nevertheless, with better selection of patients likely to benefit from hormonal therapy and the exploration of potential role after chemotherapy, one may look forward to new directions of interest.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Eng J Med 1961; 264:216–8.
Kelley RM, Baker WH. The role of progesterone in human endometrial cancer. Cancer Res 1965; 25:1190–2.
Taylor RW. In Endometrial Cancer–International Symposium Marburg 1986 – K-D Schulz, RJB King, K Pollow, and RW Taylor, Editors. Treatment of disseminated, recurrent endometrial cancer with progestational agents. W Zuckscherdt Verlag, Munchen, 1987. pp. 155–6.
Reifenstein EC. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 1974; 2: 377–414.
Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736–44.
Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19(2):364–7.
Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1): 4–9.
Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1): 10–14.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Muggia, F., Blank, S.V. (2009). Treatment of Advanced and Recurrent Carcinoma. In: Oliva, E., Muggia, F. (eds) Uterine Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60327-044-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-60327-044-1_11
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-736-5
Online ISBN: 978-1-60327-044-1
eBook Packages: MedicineMedicine (R0)